A Phase 2/3 interventional study of Sarilumab and Placebo (for sarilumab) in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 262 sites in 36 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-06-28.
Sponsored by Sanofi · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 2nd largest by enrollment, is one of 4 that started in 2010, is the only one in phase 2/3, and was the 4th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,675 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 88 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
36 studies in Arthritis, Rheumatoid by Sanofi: 2 open now, 2 under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 2nd largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2010, is the only one in phase 2/3, and was the 8th registered.
Sanofi’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 36 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objectives:
Part A (dose ranging study):
To demonstrate that sarilumab (SAR153191/REGN88) on top of MTX was effective on reduction of signs and symptoms of rheumatoid arthritis at 12 weeks.
Part B (pivotal study):
To demonstrate that sarilumab added to MTX was effective in:
Secondary Objectives:
Part B:
To demonstrate that sarilumab added to MTX was effective in induction of a major clinical response at 52 weeks
To assess the safety of sarilumab added to MTX
To document the pharmacokinetic profile of sarilumab added to MTX in participants with active rheumatoid arthritis who were inadequate responders to MTX therapy.
The total study duration for a participant was 16-22 weeks (Part A) and 56-62 weeks (Part B) broken down as follows:
'*' Participants successfully completing their treatment period would be offered the opportunity to enter the long term extension study LTS11210 (SARIL-RA-EXTEND) (NCT01146652).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active disease defined as:
Part B only:
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of MTX for 12 weeks.
Drug: Sarilumab · Drug: Methotrexate · Drug: Folic Acid
Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.
Drug: Sarilumab · Drug: Methotrexate · Drug: Folic Acid
Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.
Drug: Sarilumab · Drug: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic Acid
Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
Drug: Sarilumab · Drug: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic Acid
Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
Drug: Sarilumab · Drug: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic Acid
Placebo (for sarilumab) qw on top of MTX for 12 weeks.
Drug: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic Acid
Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).
Drug: Sarilumab · Drug: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic Acid
Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
Drug: Sarilumab · Drug: Methotrexate · Drug: Folic Acid
Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
Drug: Sarilumab · Drug: Methotrexate · Drug: Folic Acid
Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
Drug: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic Acid
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: SAR153191, REGN88
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Same weekly dose as received prior to enrollment
According to local standard
Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
ACR20 response was defined, based on guidelines set forth by the American College of Rheumatology (ACR), as ≥20 % improvement in tender joint count and swollen joint count as well as ≥20% improvement in at least 3 of 5 following measures: C-Reactive Protein (CRP), Participant assessment of pain; Participant's global assessment of disease activity; Physician global assessment of disease activity; and Health Assessment Question-Disability Index (HAQ-DI). Missing data imputed by Last Observation Carried Forward (LOCF).
Time frame: Baseline to Week 12
Part B: Percentage of Participants Achieving ACR20 Response at Week 24
ACR20 improvement responses were determined without imputation of missing post-baseline values. In addition data collected after treatment discontinuation or rescue was set to missing. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.
Time frame: Baseline to Week 24
Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16
HAQ-DI was a participant-reported questionnaire that assesses the difficulty of performing daily activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities. Overall score range from 0=least difficulty to 3=extreme difficulty. An increase in the score indicates a worsening of physical function while a decrease in the score represents improvement. Data collected after treatment discontinuation was set to missing.
Time frame: Baseline, Week 16
Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52
The Sharp method modified by D. van der Heijde involves separate scores for erosions and joint space narrowing based on radiographs to assess the degree of structural damage. Total score range from 0 (normal) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Missing data were imputed by the linear extrapolation method.
Time frame: Baseline, Week 52
Part B: Percentage of Participants Achieving a Major Clinical Response at Week 52
Major clinical response was defined as an ACR70 response maintained for at least 24 consecutive weeks. ACR70 response uses the same criteria as for ACR20 but requires 70% improvement. In the primary approach, data collected after treatment discontinuation or rescue was set to missing. No imputation of missing post-baseline values was performed. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.
Time frame: Baseline up to Week 52
The study was conducted at 247 centers in 36 countries. Overall, 3715 participants were screened between March 2010 and July 2012, 2040 of whom were screen failures. Screen failures were mainly due to failure to meet the inclusion criterion for severity of the disease and/or due to meeting the exclusion criterion.
| Milestone | Part A: SAR 100 mg qw | Part A: SAR 150 mg qw | Part A: SAR 100 mg q2w | Part A: SAR 150 mg q2w | Part A: SAR 200 mg q2w | Part A: Placebo qw | Part B Cohort 1: Non-selected Doses | Part B: SAR 150 mg q2w (Cohort 1 [Selected Dose]+Cohort 2) | Part B: SAR 200 mg q2w (Cohort 1 [Selected Dose]+Cohort 2) | Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 50 | 50 | 51 | 51 | 52 | 52 | 84 | 430 | 427 | 428 |
| Treated | 50 | 50 | 51 | 51 | 51 | 52 | 84 | 428 | 426 | 428 |
| Rescued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61 | 55 | 168 |
| Completed | 37 | 46 | 45 | 48 | 45 | 49 | 0 | 336 | 330 | 354 |
| Not completed | 13 | 4 | 6 | 3 | 7 | 3 | 84 | 94 | 97 | 74 |
| Withdrew: Dose regimen not selected | 0 | 0 | 0 | 0 | 0 | 0 | 79 | 0 | 0 | 0 |
| Withdrew: Adverse event | 13 | 1 | 3 | 2 | 4 | 1 | 4 | 63 | 67 | 34 |
| Withdrew: Lack of efficacy | 0 | 2 | 1 | 1 | 1 | 2 | 1 | 9 | 9 | 10 |
| Withdrew: Poor compliance to protocol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 9 |
| Withdrew: Not treated | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Other than specified above | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 18 | 15 | 21 |
ACR20 response was defined, based on guidelines set forth by the American College of Rheumatology (ACR), as ≥20 % improvement in tender joint count and swollen joint count as well as ≥20% improvement in at least 3 of 5 following measures: C-Reactive Protein (CRP), Participant assessment of pain; Participant's global assessment of disease activity; Physician global assessment of disease activity; and Health Assessment Question-Disability Index (HAQ-DI). Missing data imputed by Last Observation Carried Forward (LOCF).
| Percentage of participants | Part A: SAR 100 mg qw | Part A: SAR 150 mg qw | Part A: SAR 100 mg q2w | Part A: SAR 150 mg q2w | Part A: SAR 200 mg q2w | Part A: Placebo qw |
|---|---|---|---|---|---|---|
| Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 62 | 72 | 49 | 66.7 | 65.4 | 46.2 |
ACR20 improvement responses were determined without imputation of missing post-baseline values. In addition data collected after treatment discontinuation or rescue was set to missing. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.
| Percentage of participants | Part B: SAR 150 mg q2w | Part B: SAR 200 mg q2w | Part B: Placebo q2w |
|---|---|---|---|
| Part B: Percentage of Participants Achieving ACR20 Response at Week 24 | 58 | 66.4 | 33.4 |
HAQ-DI was a participant-reported questionnaire that assesses the difficulty of performing daily activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities. Overall score range from 0=least difficulty to 3=extreme difficulty. An increase in the score indicates a worsening of physical function while a decrease in the score represents improvement. Data collected after treatment discontinuation was set to missing.
| units on a scale | Part B: SAR 150 mg q2w | Part B: SAR 200 mg q2w | Part B: Placebo q2w |
|---|---|---|---|
| Baseline | 1.63 ± 0.63 | 1.69 ± 0.63 | 1.61 ± 0.65 |
| Week 16 | 1.08 ± 0.67 | 1.11 ± 0.7 | 1.31 ± 0.67 |
| Change from baseline at Week 16 | -0.54 ± 0.55 | -0.58 ± 0.63 | -0.3 ± 0.58 |
The Sharp method modified by D. van der Heijde involves separate scores for erosions and joint space narrowing based on radiographs to assess the degree of structural damage. Total score range from 0 (normal) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Missing data were imputed by the linear extrapolation method.
| units on a scale | Part B: SAR 150 mg q2w | Part B: SAR 200 mg q2w | Part B: Placebo q2w |
|---|---|---|---|
| Baseline | 54.67 ± 63.42 | 46.34 ± 57.43 | 48.01 ± 65.23 |
| Week 52 | 55.57 ± 63.73 | 46.59 ± 57.63 | 50.79 ± 65.82 |
| Change from baseline at Week 52 | 0.90 ± 4.66 | 0.25 ± 4.61 | 2.78 ± 7.73 |
Major clinical response was defined as an ACR70 response maintained for at least 24 consecutive weeks. ACR70 response uses the same criteria as for ACR20 but requires 70% improvement. In the primary approach, data collected after treatment discontinuation or rescue was set to missing. No imputation of missing post-baseline values was performed. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.
| Percentage of participants | Part B: SAR 150 mg q2w | Part B: SAR 200 mg q2w | Part B: Placebo q2w |
|---|---|---|---|
| Part B: Percentage of Participants Achieving a Major Clinical Response at Week 52 | 12.8 | 14.8 | 3 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to study completion regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: SAR 100 mg qw | — | 3/50 (6%) | 16/50 (32%) |
| Part A: SAR 150 mg qw | — | 0/50 (0%) | 16/50 (32%) |
| Part A: SAR 100 mg q2w | — | 3/51 (5.9%) | 7/51 (13.7%) |
| Part A: SAR 150 mg q2w | — | 0/52 (0%) | 12/52 (23.1%) |
| Part A: SAR 200 mg q2w | — | 0/51 (0%) | 19/51 (37.3%) |
| Part A: Placebo qw | — | 2/51 (3.9%) | 11/51 (21.6%) |
| Part B: SAR 100 mg qw Cohort 1 (Non-selected Dose) | — | 2/29 (6.9%) | 6/29 (20.7%) |
| Part B: SAR 150 mg qw Cohort 1 (Non-selected Dose) | — | 2/26 (7.7%) | 8/26 (30.8%) |
| Part B: SAR 100 mg q2w Cohort 1 (Non-selected Dose) | — | 0/29 (0%) | 6/29 (20.7%) |
| Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | — | 35/370 (9.5%) | 163/370 (44.1%) |
| Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | — | 46/369 (12.5%) | 194/369 (52.6%) |
| Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) | — | 21/259 (8.1%) | 95/259 (36.7%) |
| Part B Sarilumab Rescue: Cohort 1(Selected Doses)+Cohort2 | — | 7/284 (2.5%) | 83/284 (29.2%) |
| Event | Part A: SAR 100 mg qw | Part A: SAR 150 mg qw | Part A: SAR 100 mg q2w | Part A: SAR 150 mg q2w | Part A: SAR 200 mg q2w | Part A: Placebo qw | Part B: SAR 100 mg qw Cohort 1 (Non-selected Dose) | Part B: SAR 150 mg qw Cohort 1 (Non-selected Dose) | Part B: SAR 100 mg q2w Cohort 1 (Non-selected Dose) | Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B Sarilumab Rescue: Cohort 1(Selected Doses)+Cohort2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/50 | 0/50 | 0/51 | 0/52 | 0/51 | 0/51 | 0/29 | 1/26 | 0/29 | 0/370 | 0/369 | 0/259 | 0/284 |
| Herpes zosterInfections and infestations | 0/50 | 0/50 | 0/51 | 0/52 | 0/51 | 0/51 | 0/29 | 1/26 | 0/29 | 0/370 | 1/369 | 0/259 | 0/284 |
| DizzinessNervous system disorders | 0/50 | 0/50 | 0/51 | 0/52 | 0/51 | 0/51 | 0/29 | 1/26 | 0/29 | 0/370 | 0/369 | 0/259 | 0/284 |
| NeutropeniaBlood and lymphatic system disorders | 1/50 | 0/50 | 0/51 | 0/52 | 0/51 | 0/51 | 1/29 | 0/26 | 0/29 | 3/370 | 4/369 | 0/259 | 0/284 |
| Hip fractureInjury, poisoning and procedural complications | 0/50 | 0/50 | 0/51 | 0/52 | 0/51 | 0/51 | 1/29 | 0/26 | 0/29 | 1/370 | 0/369 | 0/259 | 0/284 |
| Alcoholic pancreatitisGastrointestinal disorders | 1/50 | 0/50 | 0/51 | 0/52 | 0/51 | 0/51 | 0/29 | 0/26 | 0/29 | 0/370 | 0/369 | 0/259 | 0/284 |
| HypersensitivityImmune system disorders | 1/50 | 0/50 | 0/51 | 0/52 | 0/51 | 0/51 | 0/29 | 0/26 | 0/29 | 0/370 | 0/369 | 0/259 | 0/284 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/50 | 0/50 | 0/51 | 0/52 | 0/51 | 1/51 | 0/29 | 0/26 | 0/29 | 0/370 | 0/369 | 0/259 | 0/284 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/50 | 0/50 | 1/51 | 0/52 | 0/51 | 0/51 | 0/29 | 0/26 | 0/29 | 0/370 | 2/369 | 1/259 | 1/284 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 0/50 | 0/51 | 0/52 | 0/51 | 1/51 | 0/29 | 0/26 | 0/29 | 0/370 | 0/369 | 0/259 | 0/284 |
| Event | Part A: SAR 100 mg qw | Part A: SAR 150 mg qw | Part A: SAR 100 mg q2w | Part A: SAR 150 mg q2w | Part A: SAR 200 mg q2w | Part A: Placebo qw | Part B: SAR 100 mg qw Cohort 1 (Non-selected Dose) | Part B: SAR 150 mg qw Cohort 1 (Non-selected Dose) | Part B: SAR 100 mg q2w Cohort 1 (Non-selected Dose) | Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B Sarilumab Rescue: Cohort 1(Selected Doses)+Cohort2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 6/50 | 5/50 | 0/51 | 1/52 | 10/51 | 0/51 | 1/29 | 2/26 | 1/29 | 36/370 | 55/369 | 0/259 | 5/284 |
| Injection site erythemaGeneral disorders | 1/50 | 1/50 | 1/51 | 0/52 | 1/51 | 0/51 | 1/29 | 3/26 | 0/29 | 20/370 | 24/369 | 2/259 | 12/284 |
| Accidental overdoseInjury, poisoning and procedural complications | 2/50 | 3/50 | 1/51 | 3/52 | 2/51 | 5/51 | 2/29 | 1/26 | 3/29 | 23/370 | 26/369 | 17/259 | 15/284 |
| Upper respiratory tract infectionInfections and infestations | 1/50 | 2/50 | 0/51 | 2/52 | 3/51 | 2/51 | 0/29 | 1/26 | 0/29 | 31/370 | 35/369 | 16/259 | 14/284 |
| Alanine aminotransferase increasedInvestigations | 2/50 | 2/50 | 0/51 | 3/52 | 2/51 | 0/51 | 0/29 | 1/26 | 0/29 | 31/370 | 30/369 | 11/259 | 9/284 |
| HypertensionVascular disorders | 0/50 | 0/50 | 2/51 | 0/52 | 0/51 | 1/51 | 1/29 | 2/26 | 2/29 | 15/370 | 14/369 | 10/259 | 5/284 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/50 | 3/50 | 1/51 | 0/52 | 0/51 | 1/51 | 2/29 | 0/26 | 0/29 | 2/370 | 10/369 | 9/259 | 12/284 |
| Urinary tract infectionInfections and infestations | 3/50 | 0/50 | 1/51 | 1/52 | 1/51 | 1/51 | 0/29 | 0/26 | 1/29 | 20/370 | 22/369 | 10/259 | 8/284 |
| NasopharyngitisInfections and infestations | 2/50 | 1/50 | 2/51 | 2/52 | 2/51 | 3/51 | 0/29 | 1/26 | 0/29 | 20/370 | 20/369 | 12/259 | 13/284 |
| BronchitisInfections and infestations | 1/50 | 2/50 | 0/51 | 1/52 | 0/51 | 0/51 | 0/29 | 1/26 | 0/29 | 12/370 | 21/369 | 12/259 | 7/284 |
| Age, Continuous(years) | Part A: SAR 100 mg qw | Part A: SAR 150 mg qw | Part A: SAR 100 mg q2w | Part A: SAR 150 mg q2w | Part A: SAR 200 mg q2w | Part A: Placebo qw | Part B Cohort 1: Non-selected Doses | Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 53.9 ± 12.3 | 50.9 ± 11.1 | 53.5 ± 11.8 | 51.2 ± 12.9 | 48.7 ± 12.4 | 55.2 ± 12.5 | 51.1 ± 11.5 | 50.3 ± 11.9 | 50.8 ± 12.0 | 51.1 ± 11.2 | 51.04 ± 11.79 |
| Sex: Female, Male(Participants) | Part A: SAR 100 mg qw | Part A: SAR 150 mg qw | Part A: SAR 100 mg q2w | Part A: SAR 150 mg q2w | Part A: SAR 200 mg q2w | Part A: Placebo qw | Part B Cohort 1: Non-selected Doses | Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 41 | 42 | 38 | 42 | 42 | 38 | 69 | 345 | 359 | 346 | 1362 |
| Male | 9 | 8 | 13 | 9 | 10 | 14 | 15 | 85 | 68 | 82 | 313 |
Showing the first 100 of 262 sites across 36 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2010, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 3 years 8 months after primary completion. A results delay was requested in Nov 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab